Stocks Technology BRGX
OTC · TechnologyBioregenx, Inc. (BRGX)
Bioregenx, Inc. brought in $1.8M of revenue over the twelve months to March 31, 2026, down 23.4% from a year earlier. It posted a net loss of $1.3M. Operating cash flow minus capital spending left $29.9K of free cash flow in fiscal 2025. At March 31, 2026 it held $45.8K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on May 20, 2026.
Watch BRGX in 60 secondsWhat Bioregenx, Inc. does
Bioregenx, Inc. is registered with the SEC under industry code SIC 7370 (Services-Computer Programming, Data Processing, Etc.). Its shares trade on OTC under the ticker BRGX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.9M | -$1.5M | $0.00 | $29.9K |
| 2024 | $2.3M | -$23.1M | -$0.03 | -$513.5K |
| 2023 | $3.4M | -$3.6M | -$0.02 | -$1.5M |
| 2022 | $42.2K | -$78.3K | $0.00 | n/a |
| 2022 | $198.6K | -$96.9K | $0.00 | n/a |
Full financial statements: income, balance sheet and cash flow
Where BRGX ranks in Technology
Latest SEC filings
What Bioregenx, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- May 20, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 17% to $426.2K versus the same quarter last year; diluted EPS $0.00 versus $0.00.
- May 15, 2026Late quarterly report notice NT 10-Q
- April 15, 2026Annual report 10-K · period to December 31, 2025Revenue fell 21% to $1.9M versus the prior year; diluted EPS $0.00 versus -$0.03.
- April 1, 2026Late annual report notice NT 10-K
- November 14, 2025Quarterly report 10-Q · period to September 30, 2025Revenue fell 15% to $507.8K versus the same quarter last year; diluted EPS $0.00 versus $0.00.
- August 14, 2025Quarterly report 10-Q · period to June 30, 2025Revenue fell 39% to $446K versus the same quarter last year; diluted EPS $0.00 versus $0.00.
- May 15, 2025
- April 16, 2025Annual report (amended) 10-K/A · period to December 31, 2024Revenue fell 31% to $2.3M versus the prior year; diluted EPS -$0.03 versus -$0.02.
- April 15, 2025Annual report 10-K · period to December 31, 2024Revenue fell 31% to $2.3M versus the prior year; diluted EPS -$0.03 versus -$0.02.
- April 14, 2025
What is BRGX worth? A DCF from its reported cash flow
Questions about BRGX
What does Bioregenx, Inc. do?
Bioregenx, Inc. is registered with the SEC under industry code SIC 7370 (Services-Computer Programming, Data Processing, Etc.). Its shares trade on OTC under the ticker BRGX.
Is Bioregenx, Inc. profitable?
No. Over the twelve months to March 31, 2026 it reported a net loss of $1.3M on revenue of $1.8M.
How much revenue does Bioregenx, Inc. make?
Over the twelve months to March 31, 2026 Bioregenx, Inc. reported revenue of $1.8M. That is 23.4% less than a year earlier.
When did Bioregenx, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on May 20, 2026. It covers the period to March 31, 2026.
Similar companies
Compare BRGX with
Follow BRGX
Get an email when Bioregenx, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow BRGX: get an email when it filesWhere the numbers come from
Financial figures are the values Bioregenx, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.